Literature DB >> 28774410

What is new on HBsAg and other diagnostic markers in HBV infection?

Christoph Höner Zu Siederdissen1, Benjamin Maasoumy2, Markus Cornberg3.   

Abstract

Challenges in the management of chronic hepatitis B virus (HBV) infection involve the prediction of the natural course to identify patients who require antiviral therapy and the prediction of functional cure as ultimate goal of antiviral therapy. HBV DNA as marker for viral replication is important but not sufficient for an adequate management of patients with chronic HBV infection. Data on the quantification of additional HBV marker such as hepatitis B surface antigen (HBsAg), hepatitis B core-related antigen (HBcrAg) and hepatitis B virus RNA (HBV RNA) have accumulated in recent years. Here we review the current evidence how to use these markers and discuss open issues that require additional research.
Copyright © 2017 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  HBV RNA; HBV infection; HBcrAg; HBsAg; Nucleos(t)ide analogues; PEG-IFN

Mesh:

Substances:

Year:  2017        PMID: 28774410     DOI: 10.1016/j.bpg.2017.04.009

Source DB:  PubMed          Journal:  Best Pract Res Clin Gastroenterol        ISSN: 1521-6918            Impact factor:   3.043


  8 in total

Review 1.  Current advances in the elimination of hepatitis B in China by 2030.

Authors:  Shuye Zhang; Fusheng Wang; Zheng Zhang
Journal:  Front Med       Date:  2017-11-23       Impact factor: 4.592

2.  Hepatitis: No cure for hepatitis B and D without targeting integrated viral DNA?

Authors:  Markus Cornberg; Michael P Manns
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2018-01-31       Impact factor: 46.802

Review 3.  The Role of Hepatitis B Core-Related Antigen.

Authors:  Takako Inoue; Yasuhito Tanaka
Journal:  Genes (Basel)       Date:  2019-05-09       Impact factor: 4.096

Review 4.  New Markers in Monitoring the Reactivation of Hepatitis B Virus Infection in Immunocompromised Hosts.

Authors:  Valentina Svicher; Romina Salpini; Vincenzo Malagnino; Lorenzo Piermatteo; Mohammad Alkhatib; Carlotta Cerva; Loredana Sarmati
Journal:  Viruses       Date:  2019-08-25       Impact factor: 5.048

5.  Farnesoid X receptor agonist for the treatment of chronic hepatitis B: A safety study.

Authors:  Robin Erken; Patrice Andre; Elise Roy; Neeltje Kootstra; Noelie Barzic; Hugo Girma; Christian Laveille; Pauline Radreau-Pierini; Raphael Darteil; Jacky Vonderscher; Pietro Scalfaro; Pisit Tangkijvanich; Robert Flisiak; Henk Reesink
Journal:  J Viral Hepat       Date:  2021-09-29       Impact factor: 3.517

6.  Characteristics of HBV Novel Serum Markers across Distinct Phases in Treatment-Naïve Chronic HBV-Infected Patients.

Authors:  Hao Liao; Le Li; Wei V Zheng; Jun Zou; Guangxin Yu; Lanlan Si; Feilin Ge; Tao Zhou; Dong Ji; Xiangmei Chen; Dongping Xu; Guanxun Cheng; Yan Liu; Junhui Chen
Journal:  Dis Markers       Date:  2022-07-14       Impact factor: 3.464

Review 7.  Drug Discovery Study Aimed at a Functional Cure for HBV.

Authors:  Takehisa Watanabe; Sanae Hayashi; Yasuhito Tanaka
Journal:  Viruses       Date:  2022-06-26       Impact factor: 5.818

Review 8.  Oxidative Stress in Chronic Hepatitis B-An Update.

Authors:  Gabriela Loredana Popa; Mircea Ioan Popa
Journal:  Microorganisms       Date:  2022-06-21
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.